M2d macrophages are activated by TLR antagonists, IL-6, and adenosine, with adenosine promoting the expression of IL-10 and VEGF, thereby exacerbating angiogenesis and tumor progression (10) (Figure 1; Table 1). The gene discussed is IL6; the disease is neoplasm.